| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From the Departments of Pathology*
and Internal
Medicine and Pharmacology
and the Hamon
Center for Therapeutic Oncology Research,
University of Texas Southwestern Medical Center, Dallas, Texas; and the
Department of Pathology,
Pontificia
Universidad Catolica de Chile, Santiago, Chile
We performed high-resolution allelotyping for loss of heterozygosity (LOH) analysis on microdissected samples from 45 primary breast cancers, 47 mammary preneoplastic epithelial foci, and 18 breast cancer cell lines, using a panel of 27 polymorphic chromosome 3p markers. Allele loss in some regions of chromosome 3p was detected in 39 of 45 (87%) primary breast tumors. The 3p21.3 region had the highest frequency of LOH (69%), followed by 3p22-24 (61%), 3p21.2-21.3 (58%), 3p25 (48%), 3p14.2 (45%), 3p14.3 (41%), and 3p12 (35%). Analysis of all of the data revealed at least nine discrete intervals showing frequent allele loss: D3S1511-D3S1284 (U2020/DUTT1 region centered on D3S1274 with a homozygous deletion), D3S1300-D3S1234 [fragile histidine triad (FHIT)/FRA3B region centered on D3S1300 with a homozygous deletion], D3S1076-D3S1573, D3S4624/Luca2.1-D3S4597/P1.5, D3S1478-D3S1029, D3S1029 (with a homozygous deletion), D3S1612-D3S1537, D3S1293-D3S1597, and D3S1597-telomere; it is more than likely that additional localized regions of LOH not examined in this study also exist on chromosome 3p. In multiple cases, there was discontinuous allele loss at several 3p sites in the same tumor. Twenty-one of 47 (45%) preneoplastic lesions demonstrated 3p LOH, including 12 of 13 (92%) ductal carcinoma in situ, 2 of 7 (29%) apocrine metaplasia, and 7 of 25 (28%) usual epithelial hyperplasia. The 3p21.3 region had the highest frequency of LOH in preneoplastic breast epithelium (36%), followed by 3p21.2-21.3 (20%), 3p14.2/FHIT region (11%), 3p25 (10%), and 3p22-24 (5%). In 39 3p loci showing LOH in both the tumor and accompanying preneoplasia, 34 (87%) showed loss of the same parental allele (P = 1.2 x 10-6, cumulative binomial test). In addition, when 21 preneoplastic samples showing LOH were compared to their accompanying cancers, 67% were clonally related, 20% were potentially clonally related but were divergent, and 13% were clonally unrelated. Overall this demonstrated the high likelihood of clonal relatedness of the preneoplastic foci to the tumors. We conclude that: chromosome 3p allele loss is a common event in breast carcinoma pathogenesis; involves multiple, localized sites that often show discontinuous LOH with intervening markers retaining heterozygosity; and is seen in early preneoplastic stages, which demonstrate clonal relatedness to the invasive cancer.
This article has been cited by other articles:
 |
|
 |
|
  B. Weissman and K. E. Knudsen Hijacking the Chromatin Remodeling Machinery: Impact of SWI/SNF Perturbations in Cancer Cancer Res., November 1, 2009; 69(21): 8223 - 8230. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Celis, P. Gromov, T. Cabezon, J. M. A. Moreira, E. Friis, K. Jirstrom, A. Llombart-Bosch, V. Timmermans-Wielenga, F. Rank, and I. Gromova 15-Prostaglandin Dehydrogenase Expression Alone or in Combination with ACSM1 Defines a Subgroup of the Apocrine Molecular Subtype of Breast Carcinoma Mol. Cell. Proteomics, October 1, 2008; 7(10): 1795 - 1809. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Wang, D. Teske, A. Tess, R. Kohlhepp, Y. Choi, C. Kendziorski, and A. R. Moser Identification of Novel Modifier Loci of ApcMin Affecting Mammary Tumor Development Cancer Res., December 1, 2007; 67(23): 11226 - 11233. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W.J. Mooi and D.S. Peeper Oncogene-induced cell senescence--halting on the road to cancer. N. Engl. J. Med., September 7, 2006; 355(10): 1037 - 1046. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Bavi, Z. Jehan, V. Atizado, H. Al-Dossari, F. Al-Dayel, A. Tulbah, S. S. Amr, S. S. Sheikh, A. Ezzat, H. El-Solh, et al. Prevalence of fragile histidine triad expression in tumors from saudi arabia: a tissue microarray analysis. Cancer Epidemiol. Biomarkers Prev., September 1, 2006; 15(9): 1708 - 1718. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Tommasi, R. Dammann, Z. Zhang, Y. Wang, L. Liu, W. M. Tsark, S. P. Wilczynski, J. Li, M. You, and G. P. Pfeifer Tumor Susceptibility of Rassf1a Knockout Mice Cancer Res., January 1, 2005; 65(1): 92 - 98. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. X. Liang, S. K. Chambers, L. Cheng, S. Zhang, Y. Zhou, and W. Zheng Endometrial Glandular Dysplasia: A Putative Precursor Lesion of Uterine Papillary Serous Carcinoma. Part II: Molecular Features International Journal of Surgical Pathology, October 1, 2004; 12(4): 319 - 331. [Abstract] [PDF]
|
|
|
|
 |
|
 S. B. Fox, P. Brown, C. Han, S. Ashe, R. D. Leek, A. L. Harris, and A. H. Banham Expression of the Forkhead Transcription Factor FOXP1 Is Associated with Estrogen Receptor {alpha} and Improved Survival in Primary Human Breast Carcinomas Clin. Cancer Res., May 15, 2004; 10(10): 3521 - 3527. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S C L Santos, L R Cavalli, I J Cavalli, R S Lima, B R Haddad, and E M S F Ribeiro Loss of heterozygosity of the BRCA1 and FHIT genes in patients with sporadic breast cancer from Southern Brazil J. Clin. Pathol., April 1, 2004; 57(4): 374 - 377. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Agathanggelou, I. Bieche, J. Ahmed-Choudhury, B. Nicke, R. Dammann, S. Baksh, B. Gao, J. D. Minna, J. Downward, E. R. Maher, et al. Identification of Novel Gene Expression Targets for the Ras Association Domain Family 1 (RASSF1A) Tumor Suppressor Gene in Non-Small Cell Lung Cancer and Neuroblastoma Cancer Res., September 1, 2003; 63(17): 5344 - 5351. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. J. Hu and A. M. Diamond Role of Glutathione Peroxidase 1 in Breast Cancer: Loss of Heterozygosity and Allelic Differences in the Response to Selenium Cancer Res., June 15, 2003; 63(12): 3347 - 3351. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kost-Alimova, H. Kiss, L. Fedorova, Y. Yang, J. P. Dumanski, G. Klein, and S. Imreh Coincidence of synteny breakpoints with malignancy-related deletions on human chromosome 3 PNAS, May 27, 2003; 100(11): 6622 - 6627. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Tan-Chiu, J. Wang, J. P. Costantino, S. Paik, C. Butch, D. L. Wickerham, B. Fisher, and N. Wolmark Effects of Tamoxifen on Benign Breast Disease in Women at High Risk for Breast Cancer J Natl Cancer Inst, February 19, 2003; 95(4): 302 - 307. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Esteller, M. Guo, V. Moreno, M. A. Peinado, G. Capella, O. Galm, S. B. Baylin, and J. G. Herman Hypermethylation-associated Inactivation of the Cellular Retinol-Binding-Protein 1 Gene in Human Cancer Cancer Res., October 15, 2002; 62(20): 5902 - 5905. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Yang, M. Nakamura, Y. Nakamura, G. Yoshimura, T. Suzuma, T. Umemura, Y. Shimizu, I. Mori, T. Sakurai, and K. Kakudo Two-Hit Inactivation of FHIT by Loss of Heterozygosity and Hypermethylation in Breast Cancer Clin. Cancer Res., September 1, 2002; 8(9): 2890 - 2893. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Shivakumar, J. Minna, T. Sakamaki, R. Pestell, and M. A. White The RASSF1A Tumor Suppressor Blocks Cell Cycle Progression and Inhibits Cyclin D1 Accumulation Mol. Cell. Biol., June 15, 2002; 22(12): 4309 - 4318. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. I. Wistuba, R. Ashfaq, A. Maitra, H. Alvarez, E. Riquelme, and A. F. Gazdar Fragile Histidine Triad Gene Abnormalities in the Pathogenesis of Gallbladder Carcinoma Am. J. Pathol., June 1, 2002; 160(6): 2073 - 2079. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Ji, M. Nishizaki, B. Gao, D. Burbee, M. Kondo, C. Kamibayashi, K. Xu, N. Yen, E. N. Atkinson, B. Fang, et al. Expression of Several Genes in the Human Chromosome 3p21.3 Homozygous Deletion Region by an Adenovirus Vector Results in Tumor Suppressor Activities in Vitro and in Vivo Cancer Res., May 1, 2002; 62(9): 2715 - 2720. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
